Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
67.60    -0.40 (-0.59%)
Bid:
67.50
Ask:
67.70
Spread: 0.20 (0.296%)
Market Cap: £597.20m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

IP Group plc - Issue of Equity

5 Apr 2018 13:12

RNS Number : 9910J
IP Group PLC
05 April 2018
 

5 April 2018

 

 

IP Group plc - Issue of Equity

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that it has issued 1,519,849 new ordinary shares of 2p each (the "New Shares") to satisfy a proportion of the deferred consideration which has become due in respect of the acquisition of Parkwalk Advisors Ltd.

An application has therefore been made to the Financial Conduct Authority for admission of the New Shares to the premium listing segment of the Official List maintained by the UK Listing Authority and to the London Stock Exchange. It is expected that admission will take place on 10 April 2018. Following the issue of New Shares, the Company will have 1,058,903,450 ordinary shares in issue.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Greg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEFKPDDBBKDKQK
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.